A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products (Glo and Glo Plus)
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Montgomery Hedgecock
- Número de teléfono: 336-741-3761
- Correo electrónico: montgomery_hedgecock@rjrt.com
Ubicaciones de estudio
-
-
-
Cheshunt, Reino Unido
- Cheshunt Community Sports Park
-
Sheffield, Reino Unido
- Channing Hall
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English.
- Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification.
- All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
- Self-report currently smoking at least five CPD on smoking days in the past 30 days.
- Smoke CC on at least 27 days out of last 30 days.
- Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV.
- Indicate a willingness to use an HTP.
- Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF.
- Agree not to allow any other person to use any product provided to them for use during this study.
Exclusion Criteria:
- Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date.
Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy.
a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy.
- Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Individuals who self-report having pacemakers or other embedded electronic medical devices.
- Individuals who self-report having an unstable heart condition, severe hypertension or diabetes.
- Individuals who self-report they are sensitive to nicotine.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company.
- Individuals who self-report that they are planning to quit all nicotine products in the next three months.
- Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs.
- People who have taken part in a tobacco/nicotine research study in the past 30 days.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: HTP Device 1
|
Tobacco Flavor
Menthol Flavor
|
|
Experimental: HTP Device 2
|
Tobacco Flavor
Menthol Flavor
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
To measure the puffing topography of primary CC smokers when using either the glo or glo plus device with one of two stick variants during a five-day use period.
Periodo de tiempo: 5 days
|
The primary endpoints of this study will be measured in using built-in topography measures and the product use behavior (PUB) instrument (Study Arm 1 only). The data will include:
|
5 days
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Determine the frequency of use of the glo and glo plus devices in Standard and Boost Mode
Periodo de tiempo: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the frequency of use of the glo plus pen detached from the charger pack (Study Arm 2 only)
Periodo de tiempo: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the average daily consumption (ADC) of CC smoked, sticks consumed, and other TNPs used
Periodo de tiempo: 5 days
|
Through self-reported questionnaires
|
5 days
|
|
Determine overall product liking and purchase intent
Periodo de tiempo: 5 days
|
Overall Product Liking: 1 (Strongly Dislike) - 10 (Strongly Like) Purchase Intent: 1 (Definitely would not purchase) - 10 (Definitely would purchase)
|
5 days
|
|
Characterize demographic characteristics
Periodo de tiempo: 5 days
|
5 days
|
|
|
Determine the safety profile (i.e., adverse events/experiences [AEs]) of the Study IP
Periodo de tiempo: 5 days
|
5 days
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Director de estudio: Melissa Tapia, Ph.D., RAIS Company
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- PHI252503
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .